Edvard de Fine Licht
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edvard de Fine Licht has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Hanna Mogensen
Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
1 shared publication - Ingrid Tonning Olsson
Department of Psychology, Lund University, Lund, Sweden; Department of Pediatrics, Skåne University Hospital, Lund, Sweden
1 shared publication - Jessica Beamish
Princess Máxima Center for Pediatric Oncology , Utrecht
1 shared publication - Jonas Lödén
Paediatrics, Skåne University Hospital , Lund
1 shared publication - Joukje Willemsen
Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publication - Marita Partanen
Princess Máxima Center for Pediatric Oncology , Utrecht
1 shared publication
Latest Publications
- Open Access
- 8 October 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Socioeconomic status and longitudinal neurocognitive outcomes following childhood brain tumor diagnosis: A Swedish national population-based cohort study
Background: Lower socioeconomic status (SES) is linked to poorer neurocognitive development in the general population, but these effects in pediatric brain tumor survivors are underexplored. We examined the relationship between parental SES, clinical factors, and neurocognitive functioning longitudinally up to 5 years post-diagnosis and determined whether young children were more vulnerable. Methods: This population-based registry study included Swedish children diagnosed with brain tumors between 2008 and 2023 and who completed ≥2 neurocognitive assessments. Parental education, occupation, and household income were used as individual SES indicators as well as a combined SES measure. Linear mixed models examined relationships between SES and age at diagnosis on neurocognitive outcomes, accounting for time since diagnosis, chemotherapy, and radiotherapy. Results: We included 461 children (mean age at diagnosis = 7.98 years, SD = 4.01). Higher SES was associated with higher neurocognitive z-scores on processing speed (B = 0.23), working memory (B = 0.25), nonverbal reasoning (B = 0.29), verbal reasoning (B = 0.41), and global cognition (B = 0.42; q’s ≤ .039). No interactions between SES and age or time were observed. Longer time since diagnosis was associated with lower processing speed (B = −0.04) and verbal reasoning (B = −0.05; q’s ≤ .041). Younger age at diagnosis was related to steeper declines in nonverbal reasoning (B = 0.01, q = .016). Cranio-spinal irradiation was related to lower processing speed (B = −0.50, q = .019). Conclusions: In Swedish childhood brain tumor survivors, lower SES was associated with poorer neurocognitive functioning over time. The absence of socioeconomic differences in rate of decline suggests that lower SES may reduce baseline cognitive reserve rather than amplifying disease or treatment-related toxicity.
- 8 October 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Open AccessSocioeconomic status and longitudinal neurocognitive outcomes following childhood brain tumor diagnosis: A Swedish national population-based cohort study
Background: Lower socioeconomic status (SES) is linked to poorer neurocognitive development in the general population, but these effects in pediatric brain tumor survivors are underexplored. We examined the relationship between parental SES, clinical factors, and neurocognitive functioning longitudinally up to 5 years post-diagnosis and determined whether young children were more vulnerable. Methods: This population-based registry study included Swedish children diagnosed with brain tumors between 2008 and 2023 and who completed ≥2 neurocognitive assessments. Parental education, occupation, and household income were used as individual SES indicators as well as a combined SES measure. Linear mixed models examined relationships between SES and age at diagnosis on neurocognitive outcomes, accounting for time since diagnosis, chemotherapy, and radiotherapy. Results: We included 461 children (mean age at diagnosis = 7.98 years, SD = 4.01). Higher SES was associated with higher neurocognitive z-scores on processing speed (B = 0.23), working memory (B = 0.25), nonverbal reasoning (B = 0.29), verbal reasoning (B = 0.41), and global cognition (B = 0.42; q’s ≤ .039). No interactions between SES and age or time were observed. Longer time since diagnosis was associated with lower processing speed (B = −0.04) and verbal reasoning (B = −0.05; q’s ≤ .041). Younger age at diagnosis was related to steeper declines in nonverbal reasoning (B = 0.01, q = .016). Cranio-spinal irradiation was related to lower processing speed (B = −0.50, q = .019). Conclusions: In Swedish childhood brain tumor survivors, lower SES was associated with poorer neurocognitive functioning over time. The absence of socioeconomic differences in rate of decline suggests that lower SES may reduce baseline cognitive reserve rather than amplifying disease or treatment-related toxicity.